Vebicorvir
- Generic Name
- Vebicorvir
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 54
- Registration Number
- NCT04781647
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Nanfang Hospital, First Military Medical University, Guangzhou, Guangdong, China
A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 2
- Registration Number
- NCT04454567
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸Asia Pacific Liver Center, Los Angeles, California, United States
🇺🇸Research and Education, San Diego, California, United States
A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 25
- Registration Number
- NCT03577171
- Locations
- 🇳🇿
Waikato Hospital, Hamilton, New Zealand
🇬🇧King's College London, London, United Kingdom
🇺🇸Southern California Research Center, Coronado, California, United States
A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 73
- Registration Number
- NCT03576066
- Locations
- 🇺🇸
Digestive Disease Associates, Catonsville, Maryland, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Placebo for ABI-H0731
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 38
- Registration Number
- NCT03109730
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇬🇧Royal London Hospital, London, United Kingdom
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Placebo for ABI-H0731Drug: Nucleos(t)ide
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 86
- Registration Number
- NCT02908191
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.